Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
648
datasets available to search
ShareScore release 0.9.0
Dataset results
648 results for “Helicobacter pylori”
The Helicobacter pylori Genome Project (HpGP) Phase1 dataset and 255 H. pylori population reference dataset
<p>This repository holds the HpGP Phase 1 genomic dataset for Hp26695 and 1011 study samples. All 1012 genomic sequences were annotated using the NCBI Prokaryotic Genome Annotation Pipeline(PGAP). Also, it has 255 curated public available H. pylori genomic sequences used for population structure analysis in Thorell et al. Nature Communications, 14:8184 (2023).</p> <p>You can check the NCBI BioProject website for the latest annotation and sequence updates.</p> <p>https://www.ncbi.nlm.nih.gov/bioproject/?term=HpGP</p> <p>Please cite the above-mentioned paper if you use the data.</p>
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
ClinicalTrials.gov study NCT03050307. IPD Sharing: YES. Countries: 4. Publications: 1.
Distinct oral-associated gastric microbiota and Helicobacter pylori communities for spatial microbial heterogeneity in gastric cancer
<p><span>STROBE Statement—Checklist of items that should be included in reports of <strong><em>case-control studies</em></strong> </span></p>
The Immunosuppressive Landscape of the Gastric Mucosa under Helicobacter pylori Infection
<p>Helicobacter pylor (H. pylori) infection triggers a complex interplay between adaptive immune responses and immune suppression. However, these combined reactions typically fail to eliminate the infection. The immune suppressive mechanisms underlying H. pylori infection at the single cell level and spatial resolution remain poorly understood. In this study, we performed single-cell RNA sequencing of the gastric mucosa from both H. pylori-infected individuals and uninfected controls. By integrating spatially resolved transcriptomics data, we identified a conserved continuum spanning from normal gastric mucosa to inflammatory regions, intestinal metaplasia, and gastric cancer. We observed spatial microenvironment heterogeneity of gastric mucosa across different pathological stages spanning beyond that previously appreciated in H. pylori infection. Through comparative analysis, We identified several pathways of T cell exhaustion and observed that the presence of exhaustion-like mucosal-associated invariant T (MAIT) cells correlates with an inflammatory environment, increased myeloid cell activity, Th17 cell expansion, and upregulation of cytokine-associated pathways. Additionally, we traced the progression of intestinal metaplasia in epithelial cells, noting the accumulation of lipid-associated enterocytes, which may interact with immune cells and contribute to the immune suppressive microenvironment. Overall, our findings offer new insights into the pathogenic mechanisms of H. pylori and suggest potential avenues for developing novel immunoprophylactic strategies.</p>
The effect of polyphenol compounds on Helicobacter pylori eradication: a systematic review with meta-analysis
<p>Objectives: Polyphenol compounds are classified as organic compounds with phenolic units exhibiting a variety of biological functions. This meta-analysis aims to assess the efficacy and safety of polyphenol compounds (curcumin, cranberry, garlic, licorice, and broccoli) in eradicating Helicobacter pylori.</p> <p>Design: Systematic review and meta-analysis.</p> <p>Data sources: These include PubMed, Embase, The Cochrane Library, Web of Science, Medline, Chinese National Knowledge Infrastructure database , Chinese Scientific Journal Database , and Wan Fang database from inception to January 2022.</p> <p>Study selection: All randomized controlled trials comparing polyphenol compounds with the placebo or used as an adjunct treatment are included in this meta-analysis.</p> <p>Data synthesis: The treatment effect for dichotomous outcomes were assessed using risk ratio, while for continuous outcomes, mean differences (MDs) both with 95% CIs, were used. Subgroup analyses were carried out for different treatment schemes and polyphenol compound species. </p> <p>Results: 12 trials were included in the meta-analysis. The total eradication rate of H.pylori in the polyphenol compounds group was higher than in the group without polyphenol compounds. Statistical significance was also observed (RR 1.19, 95% CI:1.03 to 1.38, P=0.02). The most frequent adverse effects of polyphenol compounds included diarrhea, headache, and vomiting. However, there were no differences regarding side effects between the two groups (RR 1.47, 95% CI: 0.83 to 2.58, P=0.18). In subgroup analyses, the H.pylori eradication rate regimens with polyphenols therapy was superior to that of regimens without polyphenols therapy in the polyphenols versus placebo subgroup (RR 4.23, 95% CI:1.38 to 12.95, P=0.01), polyphenols plus triple therapy versus triple therapy subgroup (RR 1.11, 95% CI: 1.01 to 1.22, P=0.03).</p> <p>Conclusion: Polyphenol compounds can improve H.pylori eradication rates. Polyphenol compounds plus standard triple therapy can significantly improve the eradication. However, no evidence of a higher incidence of side effects could be found.</p> <p>PROSPERO registration number: CRD42022307477</p>
Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt
ClinicalTrials.gov study NCT04039412. IPD Sharing: YES. Countries: 1. Publications: 14.
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
ClinicalTrials.gov study NCT00656968. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
ClinicalTrials.gov study NCT05073367. IPD Sharing: YES. Countries: 1. Publications: 1.
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
ClinicalTrials.gov study NCT03198507. IPD Sharing: NO. Countries: 1. Publications: 2.
Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication
ClinicalTrials.gov study NCT06811207. IPD Sharing: NO. Countries: 1. Publications: 3.
i-Scan for the Detection of Helicobacter Pylori
ClinicalTrials.gov study NCT02385045. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated
ClinicalTrials.gov study NCT06076681. IPD Sharing: NO. Countries: 1. Publications: 1.
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
ClinicalTrials.gov study NCT01980095. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile
ClinicalTrials.gov study NCT05926804. IPD Sharing: YES. Countries: 1. Publications: 5.
Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants
ClinicalTrials.gov study NCT06076694. IPD Sharing: NO. Countries: 1. Publications: 1.
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
ClinicalTrials.gov study NCT02159976. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Comparison of Two Rescue Therapies for Helicobacter Pylori Infection
ClinicalTrials.gov study NCT02547012. IPD Sharing: Not stated. Countries: 1. Publications: 31.
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
ClinicalTrials.gov study NCT04167670. IPD Sharing: NO. Countries: 6. Publications: 2.
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
ClinicalTrials.gov study NCT03050359. IPD Sharing: YES. Countries: 4. Publications: 1.
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
ClinicalTrials.gov study NCT03124199. IPD Sharing: UNDECIDED. Countries: 1. Publications: 20.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.